Jovanny Vargas

Statistics

Publications

Citations

H-Index

Active since

2022

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

The University of Texas Health Science Center at Houston

Jovanny Vargas is an author at The University of Texas MD Anderson Cancer Center specializing in therapeutic resistance, checkpoint inhibitor therapy, and immunotherapy.

ORCID

Publications per year

2022–2024

Publications

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma

Changying Jiang, Yang Liu, Junwei Lian et al. · Journal of Clinical Investigation · 2023 · 33 citations · Full text

Medicine, Oncology, Pharmacology +17

The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma

Fangfang Yan, Alexa A Jordan, Yuxuan Che et al. · Experimental Hematology and Oncology · 2024 · 24 citations · Full text

Medicine, Molecular Biology, Oncology +17

Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma

Lingzhi Li, Lei Nie, Alexa A Jordan et al. · Haematologica · 2022 · 18 citations · Full text

Medicine, Oncology, Pharmacology +16

Acalabrutinib with Rituximab As First-Line Therapy for Older Patients with Mantle Cell Lymphoma - a Phase II Clinical Trial

Preetesh Jain, Chi Young Ok, Loretta J. Nastoupil et al. · Blood · 2023 · 13 citations

Pharmacy, Oncology, Pharmacotherapy +15

Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins

Yijing Li, Heng‐Huan Lee, Changying Jiang et al. · Cell Death and Disease · 2023 · 11 citations · Full text

Medicine, Oncology, Pharmacology +17

1–5 of 5